TD Cowen analyst Charles Rhyee downgraded Pear Therapeutics to Market Perform from Outperform without a price target after the company said it would be exploring strategic alternatives that could include outright sale, asset divestitures and additional financing.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PEAR:
